Preparation of size selective nanocomposite through temperature assisted co-assembly of gelatin and pluronic F127 for passive targeting of doxorubicin

Ram Pada Das^{1,2}, Beena Gobind Singh^{1,2,*}, Amit Kunwar^{1,2,*}

¹Radiation & Photochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India

²Homi Bhabha National Institute, Anushaktinagar, Mumbai –400094, India

*Corresponding authors Radiation and Photochemistry Division, Bhabha Atomic Research Centre, Mumbai - 400085, India. E-mail- <u>beenam@barc.gov.in; kamit@barc.gov.in</u> Tel: 91-22-25592352, Fax: 91-22-25505151.

Supplementary Figures

Fig. S1. (A) TGA plots of pure F127, pure gelatin, and gelatin-F127 nanocomposite are presented. (B) Plot represents the CD spectra of pure F127, pure gelatin, and gelatin-F127 nanocomposite.



Fig. S2. Figures represent the concentration $(0.5 - 10 \,\mu\text{M})$ dependant cytotoxicity of free Dox and G-Dox in MCF7 (A), A549 (B), PC3 (C) and WEHI (D) cells by MTT assay after 48 h of treatment. The results are presented as mean \pm SEM (n = 3).



Fig. S3. Normalized concentration-time profile of Dox in heart, spleen, kidney, liver, and bone marrow with respect to concentration-time profile in plasma of mice after administering free Dox and G-Dox containing equivalent Dox dosage of 10 mg/kg body weight (i.v). Results are presented as mean \pm SEM (n = 3).



Fig. S4. Plots (A) and (B) respectively shows the spleen parameters like spleen cellularity and spleen index respectively in different treatment groups on day 20. Results are presented as mean \pm SEM (n = 5 - 6). * p < 0.05 as compared to the control group; # p < 0.05 as compared to free Dox group. The figures (C) show representative images of H&E stained tissue sections from spleen of different treatment groups on day 20. Magnification - 10×.

